Novel coumarin-imidazoline derivatives and process for synthesis thereof

IN595434BActive Publication Date: 2026-07-15DR SUMAN LATA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202111041810
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-09-16
Publication Date
2026-07-15
Estimated Expiration
2041-09-16

AI Technical Summary

Technical Problem

Current antimicrobial agents face challenges in efficacy and toxicity, particularly in treating bacterial and microbial infections, with a need for novel compounds that exhibit improved antimicrobial activity against Gram-positive and Gram-negative bacteria.

Method used

Development of novel coumarin-imidazoline derivatives synthesized through a process involving the reaction of halogenated coumarin derivatives with imidazoline derivatives, optimizing conditions such as temperature and solvent usage to achieve effective antimicrobial activity.

Benefits of technology

The synthesized coumarin-imidazoline derivatives demonstrate significant antimicrobial activity against Staphylococcus aureus and Escherichia coli, showcasing potential as effective and less toxic antimicrobial agents.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides novel coumarin derivatives. More specifically, it relates to novel coumarin- imidazoline derivatives (formula 1) and process for synthesis thereof. The synthesised coumarin-imidazoline derivatives (formula 1) have antimicrobial activity against gram positive bacteria, Staphylococcus aureus (MTCC 87), and gram negative bacteria, Escherichia coli (MTCC 40) with zone of inhibition in the range of 24 mm to 29.6 mm at 1000mcg / ml. [To be published with formula 1]
Need to check novelty before this filing date? Find Prior Art

Description

Field of inventionThe present invention relates to coumarin derivatives. More specifically, itrelates to coumarin-imidazoline derivatives and process for synthesisthereof. The synthesised coumarin-imidazoline derivatives showsantimicrobial activity against gram positive bacteria, Staphylococcus aureus(MTCC 87), and gram negative bacteria, Escherichia coli (MTCC 40).Background of inventionCoumarin (2H-1-benzopyran-2-one), having formula, and their derivativeshave attracted considerable attention due to their extensively biologicalactivities such as anti-inflammatory, anti-coagulant, anti-bacterial, antifungal,antiviral, anti-cancer, anti-hypertensive, anti-tubercular, anticonvulsant,anti-adipogenic, anti-hyperglycemic, anti-oxidant, anti-parasite,and neuroprotective properties.Multitudinous efforts have been taken not only towards the isolation andpurification of naturally occurring biological coumarin from a variety ofplants, animals and microorganisms, but also towards the developments ofartificial synthetic coumarin derivatives as potential drugs. Various newderivatives with coumarin ring including the furanocoumarins, pyranocoumarins and coumarin sulfamates have been found to be useful in antibacterial as well as anti-microbial activities.In recent years, many hybrid molecules with coumarin based ring systemshave been synthesized utilizing novel synthetic methodologies. Somecoumarins derivatives conjugated with nitrogen-containing heterocyclicmoieties, such as triazole, pyridine and pyrimidines, were synthesized andproved to possess biological activity. Imidazole and its derivatives are ofgreat importance in medicinal chemistry and can be used for the synthesisof myriad heterocyclic compounds with different biological activities such asantiviral, antibacterial, antifungal, anti-tuberculosis, anticancer.Keshavarzipour et al. ("synthesis of coumarin derivatives using cholinechloride / zinc chloride as a deep eutectic solvent", J. Iran. Chem. Soc. 2016;13: 149-153) discloses synthesis of coumarin derivatives in deep eutecticsolvent (DES) by Knoevenagel condensation. DES was prepared by mixingcholine chloride (ChCl) and zinc chloride at 100°C. For the synthesis ofcoumarins derivatives, simple or substituted salicylaldehydes (4-hydroxy, 5-bromo) and methylene compounds (dimethyl malonate, ethyl cyanoacetate,ethyl 3-oxo-3-phenylpropanoate) were used. The yields were high (61-96%) and DES acted both as a solvent and as catalyst.Moreover, imidazole, having formula ,based compounds such asmebendazole, levamisole, flubendazole and thiabendazole are veryimportant anti-bacterial, anti-microbial anti-parasite medicines for clinicaltreatment. 2-Aminoimidazoline derivatives were used as anti-cancer agentsthat inhibit creatine kinase (CK) and / or creatine transport. Increasedexpression of CK results in production of excess phosphocreatine whichmay be used as an energetic store for generating ATP needed to endurehepatic hypoxia. Inhibition of the phosphocreatine system through inhibitionof CK and / or creatine uptake in cancer cells is thus a therapeutic target forthe treatment of cancer (De Luca L et al. "Naturally occurring and syntheticimidazoles: their chemistry and their biological activities", Curr Med Chem2006; 13(1):1-23))Therefore, considering above mentioned importance of coumarin andimidazole / imidazoline derivatives, there is a need to develop and synthesisof novel coumarin-imidazoline hybrid derivatives which can be used asdrugs to treat patients who are at risk of infection, microbial and bacterial,and wherein the developed novel anti- microbial agents have better efficacy,as well as lower toxicity.The present invention provides novel anti-microbial agents, a series of novelcoumarin-imidazoline derivatives, are synthesized. All synthesisedderivatives are evaluated for their anti-microbial activity in vitro againstbacterial strains.Objects of the inventionMain object of the present invention is to provide novel coumarinimidazolinederivatives and process thereof.One of the objects of the present invention is to provide novel coumarinderivatives and process for synthesis thereof.Another object of the present invention is to provide novel imidazolinederivatives and process for synthesis thereof.Another object of the present invention is to evaluate biological activity forsynthesized coumarin-imidazoline derivatives.Yet another object of the present invention is to provide purification methodsfor synthesised derivatives.Summary of the inventionOne aspect of the present invention provides coumarin-imidazolinederivatives as anti-microbial agent having the general structural formula 1comprising:whereinR in the formula 1 is selected from hydrogen atom, a hydroxyl group, ahalogen group, a nitro group, a carboxy group, an aldehyde group, an aminogroup or substituted amino group, an alkyl group, a cycloalkyl group, analkoxy group, a cycloalkoxy group, an alkenyl group, a cycloalkenyl group,aryl group, an aryloxy group;R1 in the formula 1 is halogen selected from fluorine, chlorine, bromine oriodine;R2 in the formula 1 is selected from hydrogen atom, an alkyl group,cycloalkyl group, an alkenyl group, a cycloalkenyl group, an aryl group, arylgroup, an aryloxy group; andR3 and R4 in the formula 1 are independently selected from hydrogen, C1-C4 saturated or unsaturated aliphatic hydrocarbon (straight chain orbranched) groups.Another aspect of the present invention is to provide a process for synthesisof the coumarin-imidazoline derivatives of formula 1, wherein the processcomprises the steps of:a) reacting compound of formula I with compound of formula II inpresence of an acid in a solvent for a time period in the range of 1hrto 3 hrs, more specifically 2 hrs, under stirring to obtain coumarinderivatives of formula 2;b) halogenating the coumarin derivatives of formula 2 in presence ofammonium acetate in a solvent for a time period in the range of30min to 150 min to obtain halogenated coumarin derivatives offormula 3;c) synthesising imidazoline derivatives of formula 4;d) contacting halogenated derivatives of formula 3 with the imidazolinederivatives of formula 4 in a ratio of 1: 3 in a solvent at a temperaturein the range of 30°C to 60°C, more specifically 40°C to 45°C, andthen refluxed for time period in the range of 1 hr to 3 hr, specifically2 hr to obtain coumarin-imidazoline derivatives of formula 1;wherein the coumarin-imidazoline derivatives of formula 1 obtainedhave anti-microbial activity.Brief description of drawingFigure 1 shows in-vitro antimicrobial activity of synthesised coumarinimidazolinederivatives (9a-9g) with zone of inhibition (mm) against the twobacterial strains.Detailed description of the inventionFor convenience, before further description of the present disclosure,certain terms employed in the specification, and examples are collectedhere. These definitions should be read in the light of the remainder of thedisclosure and understood as by a person of skill in the art.It must also be noted that as used herein, the singular forms "a", "an," and"the" include plural references unless the context clearly dictates otherwise.Although any systems and methods similar or equivalent to those describedherein can be used in the practice or testing of embodiments of the presentinvention, the preferred, systems are now described.The terms "comprise" and "comprising" are used in the inclusive, opensense, meaning that additional elements may be included. Throughout thisspecification, unless the context requires otherwise the word "comprise",and variations, such as "comprises" and "comprising", will be understood toimply the inclusion of a stated element or step or group of element or stepsbut not the exclusion of any other element or step or group of element orsteps.The term "including" is used to mean "including but not limited to". The terms"Including" and "including but not limited to" are used interchangeably.Unless defined otherwise, all technical and scientific terms used herein havethe same meaning as commonly understood by one of ordinary skill in theart to which this disclosure belongs. Although any methods and materialssimilar or equivalent to those described herein can be used in the practiceor testing of the disclosure, the preferred methods, and materials are nowdescribed.Detailed embodiments of the present invention are disclosed herein,however, it is to be understood that the disclosed embodiments are merelyexemplary of the invention, which may be embodied in various forms.Therefore, specific functional and structural details disclosed herein are notto be interpreted as limiting, but merely as a basis for the claims and as arepresentative basis for teaching one skilled in the art to variously employthe present invention in virtually any appropriately detailed structure.Definitions:The term "derivative" used herein refers to a compound that is derived froma similar compound or a compound that can be imagined to arise fromanother compound, if one atom is replaced with another atom or group ofatoms.The term 'coumarin-imidazoline derivatives' used herein refers to acompound which is derived from the coupling of halogenated coumarinderivatives of formula 3 with the imidazoline derivatives of formula 4. In thepresent invention, 'coumarin-imidazoline derivatives' is derivative / compound of formula 1.The term 'solvent' used herein refers to a substance that can dissolveanother substance, or in which another substance is dissolved, forming asolution. The solvent used in the present invention can be polar or nonpolarsolvent. The solvent includes such as but not limit to alcohols, ethers,ketones, acids, esters, acetonitrile (ACN), and halogenated solvents.The term 'leaving group (LG)' used herein refers to a molecular fragmentthat departs with a pair of electrons in heterolytic bond cleavage. Leavinggroups can be anions, cations or neutral molecules. The leaving group beable to stabilize the additional electron density that results from bondheterolysis.The term 'pharmaceutical composition' used herein refers to a process inwhich different chemical substances, including the active drug, arecombined to produce a final medicinal product.The term 'pharmaceutically accepted carrier' used herein refers to apharmaceutically acceptable material, composition or vehicle, such as aliquid or solid filler, diluent, excipient, solvent or encapsulating material.One of the embodiments of the present invention provides coumarinimidazolinederivatives of formula 1 comprising:whereinR in the formula 1 is selected from hydrogen atom, a hydroxyl group, ahalogen group, a nitro group, a carboxy group, an aldehyde group, an aminogroup or substituted amino group, an alkyl group, a cycloalkyl group, analkoxy group, a cycloalkoxy group, an alkenyl group, a cycloalkenyl group,aryl group, an aryloxy group;R1 in the formula 1 is halogen selected from fluorine, chlorine, bromine oriodine;R2 in the formula 1 is selected from hydrogen atom, an alkyl group,cycloalkyl group, an alkenyl group, a cycloalkenyl group, an aryl group, arylgroup, an aryloxy group; andR3 and R4 in the formula 1 are independently selected from hydrogen, C1-C4 saturated or unsaturated aliphatic hydrocarbon (straight chain orbranched) groups.Another embodiment of the present invention provides a substitutedcoumarin derivatives of formula 2 and formula 3, comprising:whereinR in the formula 2 is selected from hydrogen atom, a hydroxyl group, ahalogen group, a nitro group, a carboxy group, an aldehyde group, an aminogroup or substituted amino group, an alkyl group, a cycloalkyl group, analkoxy group, a cycloalkoxy group, an alkenyl group, a cycloalkenyl group,aryl group, an aryloxy group;R1 in the formula 2 is halogen selected from fluorine, chlorine, bromine oriodine; andR2 in the formula 2 is hydrogen atom, an alkyl group, cycloalkyl group, analkenyl group, a cycloalkenyl group, an aryl group, aryl group, an aryloxygroup; and whereinR in the formula 3 is selected from hydrogen atom, a hydroxyl group, ahalogen group, a nitro group, a carboxy group, an aldehyde group, an aminogroup or substituted amino group, an alkyl group, a cycloalkyl group, analkoxy group, a cycloalkoxy group, an alkenyl group, a cycloalkenyl group,aryl group, an aryloxy group;R1 in the formula 3 is halogen selected from fluorine, chlorine, bromine oriodine;R2 in the formula 3 is selected from hydrogen atom, an alkyl group,cycloalkyl group, an alkenyl group, a cycloalkenyl group, an aryl group, arylgroup, an aryloxy group; andX in the formula 3 is halogen selected from fluorine, chlorine, bromine oriodine.Another embodiment of the present invention provides an imidazolinederivatives of formula 4 comprising:whereinR3 and R4 in the formula 4 are independently selected from hydrogen, C1-C4 saturated or unsaturated aliphatic hydrocarbon (straight chain orbranched) groups; andLG in the formula 4 is a leaving group selected from dinitrogen, dialkyl ether,perfluoroalkylsulfonates (e.g. triflate), tosylates, mesylates and similarsulfonates, iodide, bromide, water, alcohols, chloride, nitrate, phosphate,and other inorganic esters, thioether, amines, ammonia, fluoride,carboxylate, phenoxides, hydroxide, alkoxides, amides,hydride, arenide,alkanide etc.In another embodiment of the present invention there is provided a processfor synthesis of coumarin-imidazoline derivatives of formula 1, wherein theprocess comprises the steps of:a) synthesising coumarin derivatives of formula 2;b) halogenating the coumarin derivatives of formula 2 in a solvent toobtain halogenated coumarin derivatives of formula 3;c) synthesising imidazoline derivatives of formula 4; andd) contacting the halogenated coumarin derivatives of formula 3 withimidazoline derivatives of formula 4 in a solvent to obtaincoumarin-imidazoline derivatives of formula 1;wherein the coumarin-imidazoline derivatives of formula 1obtained have anti-microbial activity.In yet another embodiment of the present invention there is provided aprocess for synthesis of coumarin-imidazoline derivatives of formula 1,wherein the process comprises the steps of:a) reacting compound of formula I with compound of formula II inpresence of an acid for a time period in the range of 1hr to 3 hrs,more specifically 2 hrs, under stirring to obtain coumarin derivativesof formula 2;b) halogenating the coumarin derivatives of formula 2 in presence ofammonium acetate in a solvent for a time period in the range of30min to 150min to obtain halogenated coumarin derivatives offormula 3;c) synthesising imidazoline derivatives of formula 4;d) contacting halogenated derivatives of formula 3 with the imidazolinederivatives of formula 4 in a ratio of 1: 3 in a solvent at a temperaturein the range of 30°C to 60°C, more specifically 40°C to 45°C, andthen refluxed for time period in the range of 1 hr to 3 hr, specifically2 hr to obtain coumarin-imidazoline derivatives of formula 1.Another embodiment of the present invention provides a process forsynthesis of coumarin derivatives of formula 2, wherein compound offormula I is reacted with compound of formula II in presence of acid for atime period in the range of 1hr to 3hrs, more specifically 2 hrs under stirringto obtain coumarin derivatives of formula 2. The schematic presentation isprovided below.Another embodiment of the present invention provides a process forsynthesis of halogenated coumarin derivatives of formula 3, whereinhalogenating of coumarin derivatives of formula 2 is carried out withhalogenating agent in presence ammonium acetate in a solvent for a timeperiod in the range of 30 min to 150 min under constant stirring. Theschematic presentation is given below.Another embodiment of the present invention provides a process forsynthesis of coumarin-imidazoline derivatives of formula 1, whereinsynthesis of coumarin-imidazoline derivatives of formula 1 is carried out bycontacting halogenated derivatives of formula 3 with imidazoline derivativesof formula 4 in the ratio of 1: 3 in a solvent at a temperature in the range of30°C to 60°C, more specifically 40°C to 45°C, and then refluxed for timeperiod in the range of 1hr to 3hr, preferably 2 hr. The schematic presentationis provided below.Another embodiment of the present invention provides a process forsynthesis of imidazoline derivatives of formula 4, wherein following stepsare involved.Another embodiment of the present invention provides a process forsynthesis of coumarin-imidazoline derivatives of formula 1, wherein saidcoumarin-imidazoline derivatives including but not limited to the derivativesprovided below.In an embodiment, R in the formula 1 is an alkyl g roup or hydroxyl group oran aldehyde group.In an embodiment, alkyl group is selected from the consisting of methyl,ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl group.Another embodiment of the present invention provides a process forsynthesis of the coumarin derivatives, halogenated coumarin derivatives,imidazoline derivatives, and coumarin-imidazoline derivatives, wherein thesolvent comprises polar and / or non-polar solvent, preferably organic polarsolvent or organic non-polar solvent.In an embodiment of the present invention, the solvent is selected from thegroup including such as but not limited to pyridine, xylene, toluene, nhexane,cyclohexane, n-heptane, diethylether, diisopropylether, terbutylmethylether,acetonitrile (ACN), tetrahydrofuran, dioxane,methylethylketone, acetone, dimethylformamide, chloroform, methanol,ethanol, propanol, butanol, pentanol, ter-butanol, 2-methyl-2-butanol,acetonitrile, methylene chloride and combinations thereof.In an embodiment of the present invention, the halogenating agent isselected from the group including such as but not limited to thionyl chloride,methanesulfonyl chloride, phosphorous pentachloride, phosphoroustricholide, trichloromethanesulfonyl chloride, trimethylsilyl chloride, bromine,carbon tetrabromide, phophorous tribromide, N-Bromosuccinimide, Nbromoacetamide,boron tribromide, trimethylsilyl bromide, phosphoruspentafluoride, more preferably N-Bromosuccinimide.In an embodiment, acid is selected from hydrochloric acid, sulphuric acid,nitric acid, preferably, sulphuric acid.In an embodiment there is provided a pharmaceutically compositioncomprising coumarin-imidazoline derivatives or its salt, and apharmaceutically acceptable carrier.The details of the present invention are provided in the examples givenbelow to illustrate the invention only and therefore they should not beconstrued to limit the scope of invention.Examples:I. Synthesis of 6-chloro-7-methyl-2H-chromen-2-oneThe synthesis of 6-Chloro-7-methyl-2H-chromen-2-one was obtained byresorcinol and ethylacetoacetate, then both were mixed and kept in ice bathwhile adding sulphuric acid drop wise along with stirring for 2h on magneticstirrer. Then mixture was poured into crushed ice in 250 ml beaker, theobtained precipitates were filtered, dried, weighed for the yield of variouslysubstituted coumarin and then uncorrected melting point of all compoundswere measured. The reagent used for synthesis of 6-Chloro-7-methyl-2Hchromen-2-one were provided in the following table.TablePhysical properties:TableII. Synthesis of 3-bromo-6-chloro-7-methy-2H-chromen-2-oneThe bromination of 6-chloro-7-methyl-2H-chromen-2-one was done byadding derivative of Example I in the solution mixture of acetonitrile,ammonium acetate and N-bromo succinamide (NBS) added slowly withconstant stirring for 40 to 45 minutes on magnetic stirrer. The stirred solutionwas poured into crushed ice in 250 ml beaker, filtered, dried and yield ofrequired product was obtained. The reagents used for synthesis of (3-bromo-6-chloro-7-methy-2H-chromen-2-one) derivative were provided inthe following table.TablePhysical properties:TableIII. Synthesis of 2-amino-2-imidazolinePowdered thiourea 76gm and water 65ml were taken in a 1 litre RBF.Dimethyl sulphate (52.1ml) was then added to it. The flask was immediatelyattached to a long reflux condenser carrying a trap. The reaction wasallowed to progress spontaneously with occasional cooling as the reactionbecame more rapid and the flask filled with vapours .After the initial vigorousreaction completed, the mixture was refluxed for 2h, during which timecrystallisation took place. The mixture was cooled, and 100ml ethanol wasadded and the solid s-methylisothiouronium was separated was filtered.Washed with 50ml ethanol. A suspension of S-methylisothiouroniumsulphate (16.68gm) in doubly distilled rectified spirit was taken in a threenecked RBF equipped with a magnetic stirrer, then ethylenediaminesolution was added slowly in RBF. The reaction mixture was refluxed for18h at 120°C. The solid 2-Iminoimidazolidinuim (1.206gm) was removed byfilteration and next step was 2-Iminoimidazolidinuim was added to 18mlmethanolic solution of sodium methoxide (0.486g) and the reaction mixturewas stirred for 0.5h at room temperature and then refluxed for 1h.Thecontents of the flask were 2-amino-2-imidazoline filtered immediately toremove the inorganic residue separated. The filtrate upon vacuumdistillation and vacuum evaporation gave 0.746g as a yellowish viscousmass.Physical properties:IV. Synthesis of 6-Chloro-3-((4,5-dihydro-1H-imidazol-2-yl)amino)-7-methyl-2H-chromen-2-oneCoupling of 3-bromo-6-chloro-7-methy-2H-chromen-2-one (1mol)(derivative of example II) with 2-Amino-2-Imidazoline (3mol) (derivative ofexample III) was achieved in a methanolic solution at temperature in therange of 40-45°C, and there after refluxing for 2h. Then reaction mixturewas cooled to room temperature and treated with water and stirred at roomtemperature for 0.5h after the reaction was completed the solid was filteredand washed with CCl4 and product was obtained. The reagents used forsaid synthesis were provided in the table below.TablePhysical properties:TableCharacterization:1H NMR (DMSO-d6, 400.12 MHz, δ ppm):7.373 (br.s 1H, -NH of NH2, exchangeable), 7.791 (br.s, 1H, -NH ofimidazoline exchangeable), 3.358 (two distorted triplets, 2H each, 2-Amino-2-Imidazoline) 2.333 (d, 1H, methyl at 7th position of the chromen), 7.187(s, 1H, aromatic at 5th position of chromen), 6.939 (m, 1H, aromatic at 8thposition of chromen).V. Antimicrobial activity of synthesized compoundsAll the synthesized compounds were subjected to antimicrobial activity(Table 6.7) against Gram positive bacteria, Staphylococus aureus (MTCC3160), Gram negative bacteria, E. Coli. (MTCC 614). The primary screeningwas carried out by Agar Plate diffusion method using nutrient agar mediumfor standard and for test sample. Ciprofloxacin was used as a standard drugfor antibacterial activity and DMSO was used as control. The zone ofinhibition was observed in mm.Table: In-vitro antimicrobial activity of synthesised coumarinimidazoline derivativesThe results of in-vitro antimicrobial activity of all the novel compoundsseries from (9a-9g) were biologically evaluated for anti- bacterial activity forGram positive bacteria Staphylococus aureus (MTCC 3160), and Gramnegative bacteria E. Coli. (MTCC 614). It was observed that position four ofcoumarin ring with -CH3 (9b) showed good activity for both gram positiveand gram negative strains. It was also observed that position seven ofcoumarin (9f, 9c) with -CH3, -OH group showed good activity for Grampositive and Gram negative strains. It was found that when position sixth,eighth had had electron withdrawing groups like -Cl & -NO2 (9f, 9g) showedexcellent antimicrobial activity against both Gram positive and Gramnegative strains. In last position fifth of coumarin rings, which was withoutsubstitution showed moderate to excellent activity.So it was concluded, that final compounds 9b, 9f, 9g were good for futureantimicrobial drug to treat bacterial infection.

Claims

1. Coumarin-imidazoline derivatives as anti-microbial agent having the general structural formula 1 comprising: wherein R in the formula 1 is selected from hydrogen atom, a hydroxyl group, a halogen group, a nitro group, a carboxy group, an aldehyde group, an amino group or substituted amino group, an alkyl group, a cycloalkyl group, an alkoxy group, a cycloalkoxy group, an alkenyl group, a cycloalkenyl group, aryl group, an aryloxy group; R1 in the formula 1 is halogen selected from fluorine, chlorine, bromine or iodine; R2 in the formula 1 is selected from hydrogen atom, an alkyl group, cycloalkyl group, an alkenyl group, a cycloalkenyl group, an aryl group, aryl group, an aryloxy group; and R3 and R4 in the formula 1 are independently selected from hydrogen, C1-C4 saturated or unsaturated aliphatic hydrocarbon (straight chain or branched) group.

2. The coumarin-imidazoline derivatives as claimed in claim 1, wherein R in the formula 1 is an alkyl group or hydroxyl group or an aldehyde group.

3. The coumarin-imidazoline derivatives as claimed in claim 2, wherein alkyl group is selected from the consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl group.

4. The coumarin-imidazoline derivatives as claimed in claim 1, wherein R1 in the formula 1 is chlorine.

5. The coumarin-imidazoline derivatives as claimed in claim 1, wherein R2, R3, R4 is hydrogen atom.

6. A process for synthesis of the coumarin-imidazoline derivatives as claimed in 1 to 5, comprising the steps of: a) reacting compound of formula I with compound of formula II in presence of acid for a time period in the range of 1hr to 3 hrs, more specifically 2 hrs under stirring to obtain coumarin derivatives of formula 2; b) halogenating the coumarin derivatives of formula 2 in presence of ammonium acetate in a solvent for a time period in the range of 30min to 150min to obtain a halogenated coumarin derivatives of formula 3; c) synthesising imidazoline derivatives of formula 4; d) contacting halogenated derivatives of formula 3 with the imidazoline derivatives of formula 4 in the ratio of 1:3 in a solvent at a temperature in the range of 30°C to 60°C, more specifically 40°C to 45°C, and then refluxed for time period in the range of 1 hr to 3 hr, specifically 2 hr to obtain coumarinimidazoline derivatives of formula 1; wherein the coumarin-imidazoline derivatives of formula 1 obtained have anti-microbial activity.

7. The process for synthesis of the coumarin-imidazoline derivatives as claimed in 6; wherein the solvent is selected from alcohols, ethers, ketones, acids, esters, acetonitrile (ACN) halogenated solvent(s).

8. The process for synthesis of the coumarin-imidazoline derivatives as claimed in 6 to 7; wherein halogenating agent is selected from thionyl chloride, methanesulfonyl chloride, phosphorous pentachloride, phosphorous tricholide, trichloromethanesulfonyl chloride, trimethylsilyl chloride, bromine, carbon tetrabromide, phophorous tribromide, N-Bromosuccinimide, N-bromoacetamide, boron tribromide, trimethylsilyl bromide, phosphorus pentafluoride, preferably N-Bromosuccinimide.

9. The process for synthesis of the coumarin-imidazoline derivatives as claimed in 6; wherein acid is selected from hydrochloric acid, sulphuric acid, nitric acid, preferably, sulphuric acid.

10. A pharmaceutically composition comprising coumarin-imidazoline derivatives of formula 1 or its salt, and a pharmaceutically acceptable carrier.